Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/4/2010

rical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, uncertainties regarding our future operating results, the risk that our product candidates will not obtain the requisite regulatory approvals to commercialize or that the future sales of our product candidates may be less than expected, and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law. Condensed Consolidated Statements of Operations

(unaudited)

(in thousands)   Three months Nine monthsEnded September 30, Ended September 30,   2010 2009 2010 2009   Collaboration revenue $ 4,881 $  —  $ 11,282 $
8212;  Expenses   Research and development 6,723 1,513 16,182 6,301   General and administrative 1,067 885 3,892 2,670   Restructuring expense 4,038 —  4,038 494  Total expenses 11,828 2,398 24,112 9,465 Other income (expense) 53 29 46 120 Loss for the period before taxes 6,894 2,369 12,784 9,345 Income tax expense (recovery) — 16 (3,000) 12 Net loss $ 6,894 $ 2,385 $ 9,784   $ 9,357

Condensed Conso
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
2. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
3. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
4. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
5. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
6. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
7. OncoGenex Reports Second Quarter Financial Results
8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
10. OncoGenex Reports First Quarter Financial Results
11. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... (PCR) TECHNOLOGY: GLOBAL MARKETS , the global market for ... billion in 2013. This is estimated to grow to ... growth rate (CAGR) of 28.6%. , New digital PCR ... possibilities within the broader PCR field. The opportunities presented ...
(Date:7/11/2014)... SEATTLE , July 11, 2014  Researchers ... navigate three-dimensional images. The new technology, called Virtual ... of small structures like neurons and synapses using ... Finger,s unique technology makes 3D imaging studies orders ... resources at an unprecedented level across many areas ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
(Date:7/10/2014)... Terascala, the industry leader in HPC management ... vice president of product management for Flexera Software, has ... Terascala’s software when combined with leading compute and storage ... and most reliable solutions for processing big data. , ... and broaden its product portfolio. His leadership in startups ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... Calif., Nov. 22, 2011 Molecular diagnostics company ... board with the appointment of three initial members: ... M.D., Ph.D., and Dr. Gregory Tsongalis, Ph.D., H.C.L.D., ... science, laboratory medicine and the commercial market related ...
... 2011 Rentricity , one of the original start-up ... and Renewable Economy (NYC ACRE) cleantech support system, has ... – chosen from a field of 4,000. The award by ... Rentricity as the winner of the "Best of Water" category ...
... AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech ... compounds to regress atherosclerotic plaque, announced the recent ... Medicine, Division of Cardiology at the David Geffen ... American Heart Association (AHA) Scientific Sessions in Orlando, ...
Cached Biology Technology:GenturaDx Announces Formation of Scientific Advisory Board 2Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List 2Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List 3Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List 4Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List 5AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation 2
(Date:7/11/2014)... Cell scientists have set a "mouse TRAP" to capture ... a recent study published in the Journal of ... a technique called TRAP to extract cellular and genetic ... by scientists at the Rockefeller Institute for Medical Research ... the protein-making machinery, or ribosomes, of the cell type ...
(Date:7/11/2014)... relationships with other group members to reduce aggression and ... the strategy for grooming activities shows a certain pattern ... the scientific journal Biology Letters . , Grooming ... practiced without ulterior motives. To be groomed has hygienic ... grooming another individual can provide access to infants, mating ...
(Date:7/11/2014)... July 11, 2014 The increased risk of kidney ... in resuscitation fluids reflects the mass of HES molecules, ... , official journal of the International Anesthesia Research Society ... the harmful effect of HES on cultured human renal ... Dr Christian Wunder and colleagues of University Hospital Wrzburg, ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... at borders. Mexico, the U.S., and Canada share the ... problems. In an effort to promote active communication among ... and the Institute of Geology of the National Autonomous ... are hosting the 108th meeting of GSA,s Cordilleran Section ...
... includes a USC scientist has methodically demonstrated that a face,s ... are the key to recognizing a person. Their ... faces "holistically," appears this month in Psychological Science . ... brain functions, these results may help scientists understand rare facial ...
... describes how bacteria use a previously unknown means to defeat ... a common "housekeeping" enzyme in a way that enables the ... appears in the Proceedings of the National Academy ... warfare with one another, and many antibiotics used in medicine ...
Cached Biology News:Geological Society of America Cordilleran section meets in the heart of Mexico 2Geological Society of America Cordilleran section meets in the heart of Mexico 3Geological Society of America Cordilleran section meets in the heart of Mexico 4New research about facial recognition turns common wisdom on its head 2Team discovers how bacteria resist a 'Trojan horse' antibiotic 2
... amplification of GC-rich nucleic acids ,The ... DNA Polymerase and a proofreading polymerase, powers ... to amplify with other polymerases and other ... the blend and the unique GC-RICH Resolution ...
Chicken Aortic Smooth Muscle Cells (CAOSMC) (>500,000 cells)...
... For nucleofection of optimized cell lines in ... the nucleofection parameters. Nucleofector Kits are only ... Different cell lines can be transfected with ... are given in brackets in percent (Efficiency ...
Canine Chondrocytes (CnC) (500,000 cells)...
Biology Products: